Oppenheimer Holdings Inc Stock News

UBS Group assumed coverage on shares of Bank of America (NYSE:BAC) in a research note published on Friday, Analyst Ratings Network reports. The brokerage issued a buy rating and a $64.00 price target on the financial services provider’s stock. BAC has been the topic of a number of other research reports. Oppenheimer boosted their price […]

CVS Health Co. (NYSE:CVS) – Oppenheimer upped their FY2021 earnings estimates for CVS Health in a report released on Thursday, December 9th. Oppenheimer analyst M. Wiederhorn now anticipates that the pharmacy operator will post earnings per share of $8.03 for the year, up from their prior estimate of $7.98. Oppenheimer also issued estimates for CVS […]

Perion Network Ltd. (NASDAQ:PERI) – Equities researchers at Oppenheimer increased their FY2021 EPS estimates for Perion Network in a research report issued on Thursday, December 9th. Oppenheimer analyst J. Helfstein now forecasts that the technology company will earn $0.98 per share for the year, up from their previous forecast of $0.89. Oppenheimer has a “Outperform” […] The post Perion Network Ltd. (NASDAQ:PERI) Expected to Earn FY2021 Earnings of $0.98 Per Share appeared first on ETF Daily News .

Heading into year’s end, the Street’s professional analysts are busy putting together their predictive models, working to give investors an idea just where the mark…

Atlantic Securities upgraded shares of Yum! Brands (NYSE:YUM) from a neutral rating to an overweight rating in a research note issued to investors on Thursday, PriceTargets.com reports. The firm currently has $151.00 price target on the restaurant operators stock. A number of other equities analysts also recently commented on YUM. Oppenheimer downgraded Yum! Brands from [] The post Yum! Brands (NYSE:YUM) Raised to Overweight at Atlantic Securities appeared first on ETF Daily News .

The Lovesac Company (NASDAQ:LOVE) Oppenheimer lifted their FY2022 EPS estimates for Lovesac in a note issued to investors on Thursday, December 9th. Oppenheimer analyst B. Nagel now anticipates that the company will post earnings per share of $1.29 for the year, up from their prior forecast of $0.64. Oppenheimer currently has a Outperform rating []

Angion Biomedica (NASDAQ:ANGN) had its price objective reduced by analysts at Oppenheimer from $15.00 to $8.00 in a report issued on Friday, The Fly reports. The firm presently has an outperform rating on the stock. Oppenheimers price target would indicate a potential upside of 206.51% from the companys current price. A number of other equities []

Conns, Inc. (NASDAQ:CONN) Oppenheimer decreased their FY2022 EPS estimates for shares of Conns in a report issued on Wednesday, December 8th. Oppenheimer analyst B. Nagel now anticipates that the specialty retailer will earn $3.90 per share for the year, down from their previous forecast of $4.06. Oppenheimer also issued estimates for Conns Q4 2022 []

The Lovesac Company (NASDAQ:LOVE) Equities researchers at Oppenheimer issued their Q2 2023 EPS estimates for Lovesac in a research report issued to clients and investors on Thursday, December 9th. Oppenheimer analyst B. Nagel expects that the company will earn $0.16 per share for the quarter. Oppenheimer has a Outperform rating and a $95.00 price []

Oppenheimer (NYSE: OPY) is one of 54 public companies in the Security brokers & dealers industry, but how does it compare to its competitors? We will compare Oppenheimer to related companies based on the strength of its dividends, profitability, risk, institutional ownership, analyst recommendations, earnings and valuation. Profitability This table compares Oppenheimer and its competitors []

Oppenheimer upgraded shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) from a market perform rating to an outperform rating in a research note issued to investors on Friday morning, Analyst Ratings Network reports. Oppenheimer currently has $31.00 target price on the biotechnology companys stock, down from their previous target price of $33.00. Other equities research analysts have []

Sarepta Therapeutics (NASDAQ:SRPT) was upgraded by stock analysts at Oppenheimer from a market perform rating to an outperform rating in a research report issued to clients and investors on Thursday, Analyst Price Targets reports. The firm presently has a $125.00 price objective on the biotechnology companys stock. Oppenheimers price objective indicates a potential upside of []

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP)s share price gapped up before the market opened on Thursday . The stock had previously closed at $20.83, but opened at $21.88. Aurinia Pharmaceuticals shares last traded at $21.18, with a volume of 48,433 shares changing hands. Several brokerages recently issued reports on AUPH. Oppenheimer raised shares of Aurinia Pharmaceuticals []

Blue Owl Capital Inc. (NYSE:OWL) Equities research analysts at Oppenheimer issued their Q4 2021 earnings per share (EPS) estimates for Blue Owl Capital in a research report issued to clients and investors on Monday, December 6th. Oppenheimer analyst C. Kotowski forecasts that the company will post earnings per share of $0.11 for the quarter. [] The post Blue Owl Capital Inc. Forecasted to Earn Q4 2021 Earnings of $0.11 Per Share (NYSE:OWL) appeared first on ETF Daily News .

Visa Inc. (NYSE:V) Analysts at Oppenheimer raised their Q1 2022 earnings estimates for Visa in a note issued to investors on Tuesday, December 7th. Oppenheimer analyst D. Gabriele now forecasts that the credit-card processor will earn $1.70 per share for the quarter, up from their prior forecast of $1.69. Oppenheimer also issued estimates for []